More than 1.6 million nodules are detected incidentally each year in the US1, but only 1 in 3 patients ever receive a follow-up clinical evaluation2.
Clinical risk assessment has become a critical component of managing patients with newly discovered nodules. When less than 5% of pulmonary nodules are diagnosed as lung cancer1,2, physicians must weigh the benefit of avoiding invasive procedures and the risk of delayed intervention.
An estimated 3/4 of patients are characterized with low to moderate risk nodules, for which there is no standard approach for physicians to determine the next step for the patient's care. As a result, it takes on average 8 months for a nodule to be diagnosed as either malignant or benign2.
To assess a patient's nodule, use the Solitary Pulmonary Nodule Malignancy Risk Calculator (Mayo Model)3.